Results 1 to 10 of about 51,582 (258)

Comparison of the Antimicrobial Effect of Atorvastatin and Nano-Atorvastatin Mouthwash on Aggregatibacter Actinomycetemcomitans: An in vitro Study [PDF]

Journal of Dentistry
Background: The emergence of resistance, side effects, and the high cost of drugs indicates a need for other therapeutic alternatives with similar properties but fewer side effects.Purpose: The present study aims to compare the antimicrobial effect of ...
Atefeh Ramezani, Tahura Etezadi, Hamidreza Goli, Nafas Daraei, Majid Saeedi, Melika Mollaei, Alireza Sedighi, Abolfazl Hosseinnattaj, Hodis Ehsani   +8 more
doaj   +2 more sources

Recurrent Symptomatic Hemorrhage in Cerebral Cavernous Malformations After Discontinuation of Atorvastatin or Placebo [PDF]

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background A recent randomized prospective controlled trial demonstrated that atorvastatin for up to 2 years was safe but did not significantly alter rebleeding in cerebral cavernous malformations.
Bader Ali, Robert Shenkar, Justine Lee, Roberto J. Alcazar‐Felix, Richard E. Thompson, Agnieszka Stadnik, Georgio Sader, Sean P. Polster, Kelly D. Flemming, James K. Liao, Matthew Sorrentino, Romuald Girard, Daniel F. Hanley, Issam A. Awad   +13 more
doaj   +2 more sources

Co-Administration of Vonoprazan, Not Tegoprazan, Affects the Pharmacokinetics of Atorvastatin in Healthy Male Subjects

Frontiers in Pharmacology, 2021
Potassium-competitive acid blocker is a new class of drugs inhibiting gastric acid. It is controversial that vonoprazan showed the inhibitory activities of cytochrome P450 3A4.
Sejung Hwang, Jae-Wook Ko, Heechan Lee, Seokuee Kim, Bongtae Kim, Geun Seog Song, Jungryul Kim, Jungryul Kim   +7 more
doaj   +1 more source

A comparative study on the effects of niacin plus atorvastatin with that of fenofibrate plus atorvastatin in dyslipidemia [PDF]

Bangladesh Journal of Pharmacology, 2008
The study was designed to evaluate and compare the effects of co-administration of atorvastatin (10 mg) either with niacin (1 g) or fenofibrate (200 mg) daily for 12 weeks in 67 coronary heart disease patients with dyslipidemia. There were no significant
Selim Ahmed, A. K. M. Mosharrof Hossain, Sudhangshu R. Dey, A. K. M. Akhtaruzzaman, Mushammath Morium Siddika   +4 more
doaj   +2 more sources

CYP3A5*3 and SLCO1B1 c.521T>C Polymorphisms Influence the Pharmacokinetics of Atorvastatin and 2-Hydroxy Atorvastatin

Pharmaceutics, 2022
There is a large variability in individual responses to atorvastatin administration. This study assessed the pharmacogenetic effects of solute carrier organic anion transporter family member 1B1 (SLCO1B1, c.388A>G and c.521T>C) and cytochrome P450 3A5 ...
Jin-Woo Park, Jong-Min Kim, Hwa-Young Lee, Jihyeon Noh, Kyoung-Ah Kim, Ji-Young Park   +5 more
doaj   +1 more source

Efficacy and safety of hybutimibe in combination with atorvastatin for treatment of hypercholesteremia among patients with atherosclerotic cardiovascular disease risk equivalent: A multicenter, randomized, double-blinded phase III study

Frontiers in Cardiovascular Medicine, 2022
BackgroundTo evaluate the safety and efficacy of hybutimibe plus atorvastatin for lipid control in hypercholesterolemia patients with atherosclerotic cardiovascular disease risk equivalent.MethodsIn this double-blind phase III study, we 1:1 randomly ...
Litong Qi, Jiyan Chen, Xiaodong Li, Xiaoyong Qi, Chunhua Ding, Xiaoping Chen, Xiang Gu, Wenliang Xiao, Shuiping Zhao, Yugang Dong, Mingqi Zheng, Kai Huang, Liangqiu Tang, Xiaomei Guo, Fang Wang, Guosheng Fu, Junxia Li, Yong Huo   +17 more
doaj   +1 more source

Atorvastatin and growth, rupture of small unruptured intracranial aneurysm: results of a prospective cohort study

Therapeutic Advances in Neurological Disorders, 2021
Background and aims: The role of statins in unruptured intracranial aneurysm (UIA) growth and rupture remains ambiguous. This study sought to determine whether atorvastatin is associated with aneurysm growth and rupture in patients harboring UIA 
Jie Wang, Jiancong Weng, Hao Li, Yuming Jiao, Weilun Fu, Ran Huo, Zihan Yan, Hongyuan Xu, Jiong Zhan, Shuo Wang, Xin Du, Yong Cao, Jizong Zhao   +12 more
doaj   +1 more source

Atorvastatin alters the expression of genes related to bile acid metabolism and circadian clock in livers of mice [PDF]

PeerJ, 2017
Aim Atorvastatin is a HMG-CoA reductase inhibitor used for hyperlipidemia. Atorvastatin is generally safe but may induce cholestasis. The present study aimed to examine the effects of atorvastatin on hepatic gene expression related to bile acid ...
Wen-Kai Li, Huan Li, Yuan-Fu Lu, Ying-Ying Li, Zidong Donna Fu, Jie Liu   +5 more
doaj   +2 more sources

Atorvastatin Induced Adverse Drug Reactions among South Indian Tamils [PDF]

Journal of Clinical and Diagnostic Research, 2017
Introduction: Atorvastatin is the most widely used statin world-over. Although atorvastatin is beneficial in reducing cardiovascular morbidity and mortality, they are associated with Adverse Drug Reactions (ADRs) which are under-recognized as well as
Chandrasekaran Indumathi, Natarajan Anusha, Kolar Vishwanath Vinod, Satheesh Santhosh, Steven Aibor Dkhar   +4 more
doaj   +1 more source

Preventive effects of different doses of atorvastatin on contrast-induced acute kidney injury in patients after multiple CT perfusions

Journal of Radiation Research and Applied Sciences, 2022
The purpose of this clinical trial was to evaluate the preventive effects of different doses of atorvastatin on CI-AKI in patients after CT perfusions.
Ning Cui, Min He, Qizhen Cao, Kejun Wang, Xujia Zhou, Qiang Han, Pingzhi Hou, Chao Liu, Lungang Chen, Lin Xu   +9 more
doaj   +1 more source